Yüklüyor......

Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone

PURPOSE OF REVIEW: Giant cell tumor of bone (GCTB) is an uncommon benign primary bone tumor, consisting of receptor activator of nuclear factor kappa-B (RANK) expressing reactive osteoclast-like giant cells and neoplastic spindle-shaped cells. Denosumab was approved by FDA in 2013 and by EMA in 2014...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Curr Opin Oncol
Asıl Yazarlar: Lipplaa, Astrid, Dijkstra, Sander, Gelderblom, Hans
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Lippincott Williams & Wilkins 2019
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6613724/
https://ncbi.nlm.nih.gov/pubmed/30844887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCO.0000000000000529
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!